查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529791

抗毒素市場規模、佔有率和趨勢分析報告：按類型、類型、作用機制、最終用途、地區和細分市場進行預測，2024-2030

Anti-venom Market Size, Share & Trends Analysis Report By Species (Snake, Scorpion), By Type (Polyvalent, Monovalent), By Mode Of Action (Cytotoxic, Neurotoxic), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

抗毒素市場規模及趨勢

預計2023年全球抗蛇毒血清市場規模為11.8億美元，預估2024年至2030年複合年成長率為8.11%。這種成長歸因於毒咬傷/蜇傷發生率的上升、抗蛇毒血清治療意識的提高、開發有效治療方法的研究和開發舉措的增加以及政府措施。根據世界衛生組織 (WHO) 統計，每年約有 540 萬人被蛇咬傷。此外，全球整體每年約有 81,410 至 137,880 人死於蛇咬傷。

同樣，一些有毒物種，例如蜘蛛和蝎子，也對抗蛇毒血清治療需求的增加做出了重大貢獻。這些有毒物種的叮咬可能會導致各種嚴重的病症和急性醫療緊急情況，包括可能阻礙呼吸的嚴重癱瘓，導致出血性疾病，甚至經常導致不可逆轉的腎衰竭。人們對毒咬傷的影響及其治療需求的認知不斷提高，預計將在預測期內推動市場成長。在健康系統和資源薄弱的國家和地區，由於毒蟲叮咬而導致的這些疾病的負擔增加，凸顯了這些治療的重要性。

各種研究機構、大學和醫療公司正在努力加強抗蛇毒血清的研究和開發，以開發先進的解決方案，以提供更好的結果和結果。例如，2022 年 10 月，馬來西亞莫納什大學和安捷倫科技公司簽署了一份合作備忘錄，將在馬來西亞建立一個綜合生物學中心。該中心預計將提高該研究所的科學知識，並幫助開發更好的抗毒素藥物和其他應用生物學研究。同樣，2024 年 3 月，肯亞靈長類動物研究所宣布準備推出第一種在非洲國家生產的惡性物。各個機構的這些研究舉措預計將促進先進治療方法的開發並推動市場成長。

同樣，全球多個政府正在努力提高人們對有毒物種及其叮咬影響的認知，預計這將進一步促進市場成長。例如，2024 年 3 月，印度政府聯合衛生署(GOI) 啟動了印度預防和控制蛇咬傷國家行動計畫 (NAP-SE)。也設立了蛇咬傷求助專線，為全國五個州受蛇咬傷影響的個人和社區提供醫療服務。政府為改善毒液咬傷受害者的醫療保健而舉措的增加預計將在預測期內推動抗蛇毒血清市場的成長。

市場區隔

該報告預測了全球、區域和國家層面的收益成長，並對 2018 年至 2030 年各子區隔的最新行業趨勢進行了分析。在這項研究中，Grand View Research, Inc. 根據物種、類型、作用機制、最終用途和地區對全球抗毒液市場報告進行了細分。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章抗毒素市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 抗毒素市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章抗毒素市場：種類、估計與趨勢分析

  • 2023年及2030年種子市場佔有率
  • 細分儀表板
  • 按類型分類的全球抗毒素市場展望
  • 2018-2030年市場規模、預測及趨勢分析

第5章抗毒素市場：類型、估計和趨勢分析

  • 類型市場佔有率，2023年及2030年
  • 細分儀表板
  • 按類型分類的全球抗毒素市場展望
  • 2018-2030年市場規模、預測及趨勢分析

第6章 抗毒素市場：作用機制、估計與趨勢分析

  • 2023年及2030年作用機制市場佔有率
  • 細分儀表板
  • 按作用機制分類的全球抗毒素市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第7章抗毒素市場：最終用途、估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的全球抗毒素市場展望
  • 2018-2030年市場規模、預測及趨勢分析

第8章抗毒素市場：區域、估計和趨勢分析

  • 2023 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 2023年主要企業市場佔有率分析
    • Bharat Serums and Vaccines Limited（BSV）
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corporation
    • CSL Limited
    • Haffkine Bio-Pharmaceutical Corporation Limited
    • Incepta Pharmaceuticals Limited
    • Merck &Co., Inc.
    • Pfizer, Inc.
    • MicroPharm Limited
    • Rare Disease Therapeutics Inc.
    • South African Vaccine Producers（Pty）Ltd.
    • Medtoxin Venom Laboratories
    • Instittue of Immunology
    • Alomone Labs, Ltd.
    • Sigma Aldrich
Product Code: GVR-4-68040-357-6

Anti-venom Market Size & Trends

The global anti-venom market size was estimated at USD 1.18 billion in 2023 and is expected to grow at a CAGR of 8.11% from 2024 to 2030. This growth is attributed to the rising prevalence of venom bites/stings, increasing awareness of anti-venom treatments, growing research initiatives to develop effective treatments, and growing government initiatives to spread. According to the World Health Organization (WHO), approximately 5.4 million people get bitten by snakes each year. Moreover, around 81 410 to 137 880 mortalities occur globally each year as a result of snake bites.

Similarly, several venomous species, such as spiders, scorpions, and others, also significantly contribute to the increasing demand for anti-venom treatments. Bites from these venomous species often lead to various serious conditions and acute medical emergencies such as severe paralysis, which may prevent breathing, lead to bleeding disorders, and may even cause irreversible kidney failure. The increasing awareness about these effects of venom bites and the need for their treatment are expected to fuel the market growth over the forecast period. The countries and regions with weaker health systems and resources experience an increased burden of these conditions caused by venom bites, highlighting the importance of these treatments.

Various research institutes, universities, and healthcare companies are taking initiatives to enhance their R&D on anti-venom for the development of advanced solutions with better results and outcomes. For instance, in October 2022, Monash University Malaysia and Agilent Technologies Inc. signed a MoU for building an integrated biology center in Malaysia. This center is anticipated to help the institutions improve their scientific knowledge to develop better anti-venom & other applied biology research. Similarly, in March 2024, the Institute for Primate Research Kenya announced that it is ready to introduce the first-ever anti-venom produced in any African country. Such research initiatives taken by various institutions are expected to lead to the development of advanced treatments and drive market growth.

Similarly, several governments globally are trying to increase awareness about venomous species and the effects of their bites, which is further anticipated to contribute to market growth. For instance, in MAR 2024, the Union Health Ministry of the Government of India (GOI) launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) in India. A snakebite helpline no was also launched at the event to ensure better access to medical care for the individuals or communities affected by snakebites in five different states of the country. Such increasing government initiatives to increase medical care access for venom bite victims are anticipated to fuel the anti-venom market growth over the forecast period.

Global Anti-venom Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global anti-venom market report based on species, type, mode of action, end-use, and region:

  • Species Outlook (Revenue, USD Million, 2018 - 2030)
  • Snake
  • Common Cobra
  • Common Krait
  • Russell Viper
  • Others
  • Scorpion
  • Spider
  • Other Species
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Polyvalent
  • Monovalent
  • Mode Of Action Outlook (Revenue, USD Million, 2018 - 2030)
  • Cytotoxic
  • Neurotoxic
  • Haemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Regional Outlook (Revenue in USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Species
    • 1.2.2. Type
    • 1.2.3. Mode of Action
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Species outlook
    • 2.2.2. Type outlook
    • 2.2.3. Mode of Action outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anti-Venom Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidents of venom-bites
      • 3.2.1.2. Increasing R&D initiatives
      • 3.2.1.3. Increasing awareness about importance of anti-venom
      • 3.2.1.4. Rising government initiatives
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited access to the treatments
  • 3.3. Anti-Venom Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.2. PESTEL Analysis

Chapter 4. Anti-Venom Market: Species Estimates & Trend Analysis

  • 4.1. Species Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Anti-Venom Market by Species Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Snakes
      • 4.4.1.1. Snakes market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Common cobra
      • 4.4.1.2.1. Common cobra market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Common krait
      • 4.4.1.3.1. Common krait market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Rusell viper
      • 4.4.1.4.1. Rusell viper market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Scorpion
      • 4.4.2.1. Scorpion market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Spider
      • 4.4.3.1. Spider market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Other species
      • 4.4.4.1. Other species market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anti-Venom Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Anti-Venom Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Polyvalent
      • 5.4.1.1. Polyvalent market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Monovalent
      • 5.4.2.1. Monovalent market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

  • 6.1. Mode of action Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Anti-Venom Market by Mode of Action Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cytotoxic
      • 6.4.1.1. Cytotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Neurotoxic
      • 6.4.2.1. Neurotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Haemotoxic
      • 6.4.3.1. Haemotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Cardiotoxic
      • 6.4.4.1. Cardiotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Myotoxic
      • 6.4.5.1. Myotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anti-Venom Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Anti-Venom Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Hospitals
      • 7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Clinics
      • 7.4.2.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Ambulatory surgical centers
      • 7.4.3.1. Ambulatory surgical centers market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Others
      • 7.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Anti-Venom Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Denmark
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Norway
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/ Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Bharat Serums and Vaccines Limited (BSV)
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Others benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Boehringer Ingelheim International GmbH
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Others benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Boston Scientific Corporation
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Others benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. CSL Limited
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Others benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Haffkine Bio-Pharmaceutical Corporation Limited
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Others benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Incepta Pharmaceuticals Limited
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Others benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Merck & Co., Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Others benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Pfizer, Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Others benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. MicroPharm Limited
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Others benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Rare Disease Therapeutics Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Others benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. South African Vaccine Producers (Pty) Ltd.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Others benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Medtoxin Venom Laboratories
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Others benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Instittue of Immunology
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Others benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. Alomone Labs, Ltd.
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Others benchmarking
      • 9.3.17.4. Strategic initiatives
    • 9.3.18. Sigma Aldrich
      • 9.3.18.1. Company overview
      • 9.3.18.2. Financial performance
      • 9.3.18.3. Others benchmarking
      • 9.3.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 4 North America anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 6 North America anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 8 U.S. anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 9 U.S. anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 10 U.S. anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 12 Canada anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 13 Canada anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 14 Canada anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 16 Mexico anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 17 Mexico anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 18 Mexico anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 21 Europe anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 22 Europe anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 23 Europe anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 25 Germany anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 26 Germany anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 27 Germany anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 29 UK anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 30 UK anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 31 UK anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 33 France anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 34 France anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 35 France anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 37 Italy anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 38 Italy anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 39 Italy anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 41 Spain anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 42 Spain anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 43 Spain anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 45 Denmark anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 46 Denmark anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 47 Denmark anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 49 Sweden anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 50 Sweden anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 51 Sweden anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 53 Norway anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 54 Norway anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 55 Norway anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 62 China anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 63 China anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 64 China anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 66 Japan anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 67 Japan anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 68 Japan anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 70 India anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 71 India anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 72 India anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 74 South Korea anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 75 South Korea anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 76 South Korea anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 78 Australia anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 79 Australia anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 80 Australia anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 82 Thailand anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 83 Thailand anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 84 Thailand anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 86 Latin America anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 87 Latin America anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 88 Latin America anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Brazil anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 90 Brazil anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 91 Brazil anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 92 Brazil anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 93 Argentina anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 94 Argentina anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 95 Argentina anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 96 Argentina anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 97 MEA anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 99 MEA anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 100 MEA anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 101 MEA anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 102 South Africa anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 103 South Africa anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 104 South Africa anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 105 South Africa anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 110 UAE anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 111 UAE anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 112 UAE anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 113 UAE anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 114 Kuwait anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 115 Kuwait anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 117 Kuwait anti-venom market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Anti-venom market: market outlook
  • Fig. 14 Anti-venom competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Anti-venom market driver impact
  • Fig. 20 Anti-venom market restraint impact
  • Fig. 21 Anti-venom market strategic initiatives analysis
  • Fig. 22 Anti-venom market: Species movement analysis
  • Fig. 23 Anti-venom market: Species outlook and key takeaways
  • Fig. 24 Snakes market estimates and forecast, 2018 - 2030
  • Fig. 25 Common Cobra market estimates and forecast, 2018 - 2030
  • Fig. 26 Common Krait market estimates and forecast, 2018 - 2030
  • Fig. 27 Russell Viper market estimates and forecast, 2018 - 2030
  • Fig. 28 Others market estimates and forecast, 2018 - 2030
  • Fig. 29 Scorpion market estimates and forecast, 2018 - 2030
  • Fig. 30 Spider market estimates and forecast, 2018 - 2030
  • Fig. 31 Other species market estimates and forecast, 2018 - 2030
  • Fig. 32 Anti-venom Market: Type movement analysis
  • Fig. 33 Anti-venom market: Type outlook and key takeaways
  • Fig. 34 Polyvalent market estimates and forecasts, 2018 - 2030
  • Fig. 35 Monovalent market estimates and forecasts, 2018 - 2030
  • Fig. 36 Anti-venom market: Mode of action movement analysis
  • Fig. 37 Anti-venom market: Mode of action outlook and key takeaways
  • Fig. 38 Cytotoxic market estimates and forecast, 2018 - 2030
  • Fig. 39 Neurotoxic market estimates and forecast, 2018 - 2030
  • Fig. 40 Haemotoxic market estimates and forecast, 2018 - 2030
  • Fig. 41 Cardiotoxic market estimates and forecast, 2018 - 2030
  • Fig. 42 Myotoxic market estimates and forecast, 2018 - 2030
  • Fig. 43 Others market estimates and forecast, 2018 - 2030
  • Fig. 44 Anti-venom market: End use movement analysis
  • Fig. 45 Anti-venom market: End use outlook and key takeaways
  • Fig. 46 Hospitals market estimates and forecasts,2018 - 2030
  • Fig. 47 Clinics market estimates and forecasts,2018 - 2030
  • Fig. 48 Ambulatory surgical centers market estimates and forecasts,2018 - 2030
  • Fig. 49 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 50 Clinical Laboratories market estimates and forecasts,2018 - 2030
  • Fig. 51 Others market estimates and forecasts, 2018 - 2030
  • Fig. 52 Global Anti-venom market: Regional movement analysis
  • Fig. 53 Global Anti-venom market: Regional outlook and key takeaways
  • Fig. 54 Global Anti-venom market share and leading players
  • Fig. 55 North America market share and leading players
  • Fig. 56 Europe market share and leading players
  • Fig. 57 Asia Pacific market share and leading players
  • Fig. 58 Latin America market share and leading players
  • Fig. 59 Middle East & Africa market share and leading players
  • Fig. 60 North America, by country
  • Fig. 61 North America
  • Fig. 62 North America market estimates and forecasts, 2018 - 2030
  • Fig. 63 U.S. key country dynamics
  • Fig. 64 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 65 Canada key country dynamics
  • Fig. 66 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 67 Mexico key country dynamics
  • Fig. 68 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 69 Europe
  • Fig. 70 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 71 UK key country dynamics
  • Fig. 72 UK market estimates and forecasts, 2018 - 2030
  • Fig. 73 Germany key country dynamics
  • Fig. 74 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 75 France key country dynamics
  • Fig. 76 France market estimates and forecasts, 2018 - 2030
  • Fig. 77 Italy key country dynamics
  • Fig. 78 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 79 Spain key country dynamics
  • Fig. 80 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 81 Denmark key country dynamics
  • Fig. 82 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 83 Sweden key country dynamics
  • Fig. 84 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 85 Norway key country dynamics
  • Fig. 86 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 87 Asia Pacific
  • Fig. 88 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 89 China key country dynamics
  • Fig. 90 China market estimates and forecasts, 2018 - 2030
  • Fig. 91 Japan key country dynamics
  • Fig. 92 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 93 India key country dynamics
  • Fig. 94 India market estimates and forecasts, 2018 - 2030
  • Fig. 95 Australia key country dynamics
  • Fig. 96 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 97 South Korea key country dynamics
  • Fig. 98 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 99 Thailand key country dynamics
  • Fig. 100 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 101 Latin America
  • Fig. 102 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 103 Brazil key country dynamics
  • Fig. 104 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 105 Argentina key country dynamics
  • Fig. 106 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 107 Middle East and Africa
  • Fig. 108 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 109 South Africa key country dynamics
  • Fig. 110 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 111 Saudi Arabia key country dynamics
  • Fig. 112 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 113 UAE key country dynamics
  • Fig. 114 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 115 Kuwait key country dynamics
  • Fig. 116 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 117 Market share of key market players - Anti-venom market